Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime to Present Additional Data at Upcoming ARVO
April 24, 2017

Retinal tissue regeneration presentation added

OpRegen® presentation scheduled for May 8


ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Maryland, May 7-11.

“This presentation is in addition to the poster presentation based on data from our Phase I/IIa clinical trial of OpRegen in the advanced form of dry-AMD. Ophthalmology is one of BioTime’s core areas of near-term strategic focus. We are leveraging our expertise in regenerative ophthalmology to build a strong pipeline of therapeutics to address a large number of degenerative diseases of the eye,” said Adi Mohanty, Co-Chief Executive Officer of BioTime.

OpRegenhas received Fast Track designation from the FDA for treatment of the advanced form of dry-AMD. Details of the trial and about a patient’s eligibility are available at with the following Identifier: NCT02286089 (dry-AMD).

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list:


Source: BioTime, Inc.

Investor Contact:
EVC Group, Inc.
Brian Moore, 310-770-0389
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890